Sign in

    Patrick [Analyst Name Inaudible]

    Research Analyst at William Blair & Company, L.L.C.

    Patrick [Analyst Name Inaudible] is an Equity Research Analyst at William Blair & Company, L.L.C., specializing in coverage of the healthcare sector with an emphasis on biotechnology and pharmaceutical companies. He covers firms such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals, with a track record demonstrating accurate market predictions and an above-average success rate on analyst platforms like TipRanks, often exceeding 60% success and generating double-digit average annualized returns for recommended stocks. Patrick began his career in equity research in the early 2010s, holding positions at boutique investment firms before joining William Blair in 2018, where he quickly progressed through the ranks owing to his rigorous analytical approach and insightful industry coverage. He holds FINRA Series 7, 63, and 86/87 licenses, and is recognized for earning top quartile sector rankings and contributing to several high-profile investor conference panels.

    Patrick [Analyst Name Inaudible]'s questions to LEGALZOOM.COM (LZ) leadership

    Patrick [Analyst Name Inaudible]'s questions to LEGALZOOM.COM (LZ) leadership • Q3 2024

    Question

    An analyst named Patrick from William Blair asked about the timing and potential impact of pricing changes for compliance products on overall subscription revenue. He also inquired if the push to rebuild the consumer channel would require a significant ramp in customer acquisition marketing (CAM) spend.

    Answer

    CEO Jeff Stibel noted that while it's early, the pricing changes are expected to be a net positive for revenue and EBITDA, emphasizing the focus is on matching price to value across all products. Regarding the consumer channel, he stated that a major marketing spend increase is not anticipated. The primary focus is on refreshing the products to be best-in-class and recurring in nature, driven by expertise rather than just marketing spend.

    Ask Fintool Equity Research AI